Glaucoma News and Research RSS Feed - Glaucoma News and Research

While there are many causes of glaucoma, most cases are associated with increased intraocular pressure. Loss of vision is usually characterized by a gradual reduction in peripheral vision, which can lead to a tunnel vision effect. Glaucoma affects approximately 100 million people globally and is one of the leading causes of blindness in the world today. An estimated three million Americans have this sight-threatening disease. Because it is painless and advances gradually, many people who have glaucoma or elevated IOP have not been diagnosed. If detected and treated early, vision can usually be preserved.
Wearable collision warning device may help patients with peripheral vision loss

Wearable collision warning device may help patients with peripheral vision loss

People who have lost some of their peripheral vision, such as those with retinitis pigmentosa, glaucoma, or brain injury that causes half visual field loss, often face mobility challenges and increased likelihood of falls and collisions. [More]
IRIDEX's new Cyclo G6 laser system now available for treatment of patients with glaucoma

IRIDEX's new Cyclo G6 laser system now available for treatment of patients with glaucoma

IRIDEX Corporation announced the first commercial sales of its new Cyclo G6 laser system, designed to treat patients diagnosed with a range of glaucoma disease states. The Cyclo G6 system includes a glaucoma dedicated laser along with a family of single use probes, including the newly patented MicroPulse P3 disposable. [More]
Medicine-loaded nanoparticles could help patients achieve corneal transplant success

Medicine-loaded nanoparticles could help patients achieve corneal transplant success

There are about 48,000 corneal transplants done each year in the U.S., compared to approximately 16,000 kidney transplants and 2,100 heart transplants. Out of the 48,000 corneal transplants done, 10 percent of them end up in rejection, largely due to poor medication compliance. This costs the health care system and puts undue strain on clinicians, patients and their families. [More]
InMed, University of Debrecen partner to develop novel therapies to treat ocular allergies

InMed, University of Debrecen partner to develop novel therapies to treat ocular allergies

InMed Pharmaceuticals Inc. announces it has formed an exclusive strategic collaboration with the University of Debrecen, Hungary, to develop novel phytocannabinoid-based therapies to treat ocular allergic symptoms. [More]
Simple training can improve vision in older adults

Simple training can improve vision in older adults

Just a weeks' worth of training can improve vision in older adults, according to new research in Psychological Science, a journal of the Association for Psychological Science. The findings show that training boosted older adults' sensitivity to contrast and also their ability to see things clearly at close distances. [More]
Severe mortality-associated diseases less prevalent in members of long-lived families

Severe mortality-associated diseases less prevalent in members of long-lived families

Recent research from the Long Life Family Study (LLFS) confirms that severe mortality-associated diseases are less prevalent in the families of long-lived individuals than in the general population. The Journals of Gerontology, Series A will publish these findings in the article titled, "Are Members of Long-Lived Families Healthier than Their Equally Long-Lived Peers? Evidence from the Long Life Family Study" on March 5, 2015. [More]
Orthokeratology technique slows progression of myopia in children

Orthokeratology technique slows progression of myopia in children

A technique called orthokeratology ("Ortho-K")--using custom-made contact lenses to shape the growing eye--has a significant effect in slowing the progression of myopia (nearsightedness) in children, according to a research review in the March issue of Optometry and Vision Science, official journal of the American Academy of Optometry. [More]
IRIDEX to unveil Cyclo G6 laser system for treatment of glaucoma at AGS annual congress

IRIDEX to unveil Cyclo G6 laser system for treatment of glaucoma at AGS annual congress

IRIDEX Corporation today announced that it will debut Cyclo G6, the Company's first laser platform dedicated to the treatment of glaucoma, at this year's annual congress of the American Glaucoma Society. [More]
IUPUI's Jason Meyer awarded $1.8 million NIH grant to explore how glaucoma develops in stem cells

IUPUI's Jason Meyer awarded $1.8 million NIH grant to explore how glaucoma develops in stem cells

Jason Meyer, Ph.D., assistant professor of biology in the School of Science at Indiana University-Purdue University Indianapolis, has received a National Institutes of Health grant to study how glaucoma develops in stem cells created from skin cells genetically predisposed to the disease. [More]
Scientists identify promising new therapeutic target for prostate cancer

Scientists identify promising new therapeutic target for prostate cancer

Keck Medicine of the University of Southern California scientists have found a promising new therapeutic target for prostate cancer. The findings offer evidence that a newly discovered member of a family of cell surface proteins called G-protein coupled receptors (GPCRs) promotes prostate cancer cell growth. The protein, GPR158, was found while the researchers were looking for new drug targets for glaucoma. [More]
Understanding the pattern of cellular changes that lead to retinal ganglion cell death in glaucoma

Understanding the pattern of cellular changes that lead to retinal ganglion cell death in glaucoma

Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular changes and how they influence the progression and severity of glaucoma, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute turned to a mouse model of the disease. [More]

OIB Program helps older Californians with blindness to live and work independently

More than ever, older Californians are facing the threat of blindness from age-related eye diseases such as diabetic retinopathy, macular degeneration, cataracts and glaucoma. [More]
New study shows that 25% of homeless people in Toronto have vision problems

New study shows that 25% of homeless people in Toronto have vision problems

Twenty-five per cent of homeless people surveyed in Toronto had vision problems up to and including blindness, four times higher than the rate of the overall population in North America, a new study by St. Michael's Hospital has found. [More]
Study: Lower-income students in China have better vision compared to middle-class counterparts

Study: Lower-income students in China have better vision compared to middle-class counterparts

In one of the largest population-based studies ever conducted on nearsightedness in children, researchers have discovered that lower-income students in China have better vision than their middle-class counterparts. Data show that nearsightedness, also called myopia, is twice as prevalent in the middle-income province of Shaanxi compared to the poorer neighboring province of Gansu. [More]
IRIDEX Cyclo G6 Laser System receives FDA clearance for treatment of glaucoma

IRIDEX Cyclo G6 Laser System receives FDA clearance for treatment of glaucoma

IRIDEX Corporation today announced that it has received clearance from the U.S. Food and Drug Administration to market its first laser system designed solely for use in treating glaucoma and its symptoms. Specifically, the Company was granted 510(k) clearance for the IRIDEX Cyclo G6 Laser System (with delivery devices). [More]

Abbott's new TECNIS Multifocal IOLs now available in the U.S. for people with cataracts

Two new intraocular lenses (IOLs) that restore vision to people with cataracts are now available in the United States. The new TECNIS Multifocal IOLs, developed by Abbott, provide people with cataracts options to have a full range of near, intermediate and distance vision, while customizing their treatment based on their personal vision needs and lifestyle. [More]
Scientists identify new molecular pathway that controls axonal degeneration following injury

Scientists identify new molecular pathway that controls axonal degeneration following injury

Axons connect neurons with each other to form the neural networks that underpin the vital functions of perception, motility, cognition, and memory. In many neurodegenerative disorders, from traumatic injury or toxic damage to diseases such as Alzheimer's or Parkinson's disease, axonal degeneration represents an essential pathological feature. [More]
New discovery may help doctors develop better treatments for brain, spinal cord injuries

New discovery may help doctors develop better treatments for brain, spinal cord injuries

In a discovery that could dramatically affect the treatment of brain and spinal cord injuries, researchers have identified a previously unknown, beneficial immune response that occurs after injury to the central nervous system. [More]
UAB Research Probes Molecular Basis Of Rare Genetic Disorder

UAB Research Probes Molecular Basis Of Rare Genetic Disorder

An international group co-led by University of Alabama at Birmingham researcher Mary MacDougall, Ph.D., has unraveled the molecular basis for the rare, inherited genetic disorder, Singleton-Merten Syndrome (SMS). Individuals with SMS develop extreme, life-threatening calcification of the aorta and heart valves, early-onset periodontitis and root resorption of the teeth, decreases in bone density, and loss of bone tissue at the tips of fingers and toes. [More]
BioLight invests in newly-formed ophthalmic company

BioLight invests in newly-formed ophthalmic company

BioLight Life Sciences Investments Ltd., a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops. [More]
Advertisement
Advertisement